Diflucan Pregnancy Risk for Birth Defects Evaluated in New Study

A new study that examined the potential pregnancy side effects of Diflucan indicates that the antifungal drug may be related to an increased risk of congenital heart defects in children, but failed to find evidence of a significantly increased risk of birth defects overall.

Danish researchers published their findings this week in the New England Journal of Medicine (NEJM), in a study designed to evaluate whether low doses of the Pfizer medication carry the same risk of birth defects that have been seen in case reports involving long-term, high-dose treatments of Diflucan.

Diflucan (fluconazole) is a prescription drug introduced by Pfizer used to treat yeast infections of the vagina, mouth, esophagus and other organs. It is also used to treat some kinds of meningitis and used as a yeast infection preventative in patients being treated with chemotherapy or radiation therapy before receiving a bone marrow transplant.

Do You Know About...

Childhood Diabetes Lawsuits Against Junk Food Industry

Lawyers are now pursuing financial compensation for families of children diagnosed with Type II diabetes, fatty liver disease and other chronic illnesses caused by addictive and harmful substances in ultra-processed foods.

In recent years, case reports have suggested that Diflucan side effects cause a pattern of birth defects when high-doses of the medication are used to treat severe fungal infections during pregnancy.

In this latest study, researchers isolated those birth defects into 15 specific types and conducted a registry-based cohort study of liveborn infants in Denmark, correlating data on first-trimester exposure to Diflucan and the rate of birth defects.

Researchers determined that Diflucan exposure was not associated with an overall increased risk of birth defects. Of the 15 different types identified in earlier studies, there was only a significantly increased risk of one; tetralogy of Fallot. The congenital heart defect occurred in one out of 1,000 cases of first-trimester Diflucan exposure, compared to 3 out of every 10,000 occurrences in other pregnancies.

Tetralogy of Fallot involves three to four cyanotic heart abnormalities that result in low oxygenation of the blood as oxygenated and deoxygenated blood is mixed in the left ventrical of the heart. It is the most common cause of what is known as blue baby syndrome.

In August 2011, the FDA issued a drug safety communication about the potential Diflucan pregnancy risks, warning that the agency was changing high doses of Diflucan from a Category C to a Category D pregnancy drug, meaning that there was positive human evidence of a risk of birth defects. The agency did not change the category for single, low-dose uses, but high doses were associated with a number of rare and distinct birth defects and congenital anomalies.

Case studies have linked Diflucan to birth defects when taken in the first trimester, at time when many woman do not even know they are pregnant. According to the FDA, birth defects seen in infants exposed to long-term, high-doses of Diflucan during the first trimester included abnormal head, skull and face defects, cleft palate, cleft lip, bowing of the thigh bones, thin ribs, long bones, muscle weakness, joint deformities and congenital heart disease at birth.

0 Comments

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page*
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Lawyers in Suboxone Dental Lawsuits Fail To Reach Agreement on Bellwether Selection Process
Lawyers in Suboxone Dental Lawsuits Fail To Reach Agreement on Bellwether Selection Process (Posted yesterday)

Plaintiffs involved in Suboxone dental lawsuits indicate the bellwether selection process may be delayed due to the defendants' approach to the discovery process, which they say will cause significant delays in the litigation.